CERO...21s clearing here off my .08 Range Alert...🥳
georgie18
Member Level
Re: georgie18 post# 165
Monday, November 11, 2024 8:28:09 AM
Post#
167
of 180
CERO...175...Off my .08 range alert...🥳
georgie18
Member Level
Re: georgie18 post# 664359
Monday, November 11, 2024 8:24:01 AM
Post#
664360
of 664360
CERO...14s clearing here off my .08 range alert...🥳
georgie18
Member Level
Re: georgie18 post# 163
Monday, November 11, 2024 8:20:29 AM
Post#
164
of 164
CERO....10s clearing here off my .08 Range Alert...🥳...Another patience play...SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ovarian cancer cells in preclinical models with no indications of toxicity in animal models. The data were presented in a poster at the Society for Immunology of Cancer (SITC) 2024 conference held in Houston November 6-10, 2024.
Interim CEO Chris Ehrlich commented, “We have long contended that CER-1236 has application in multiple cancer types. While we await the opportunity to introduce our compound into the clinic for AML, we continue to see other models in which there is utility and minimal-to-no toxicity. These data are of particular interest as the Company plans to apply for Orphan designation at the appropriate time in clinical development. Regardless, these data are further confirmation that our approach has enormous potential to go beyond some of the limitations of current chemotherapy approaches.”
The study, titled, “TIM-4 Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity,” investigators assessed CER-1236 on the immune receptor TIM-4-L in ovarian cancer cell lines. Results demonstrated that following the introduction of CER-1236 on these cell lines, TIM-4-L increased, which then responded with the killing of the cancer cells, but with no observed toxicity to healthy cells. The study further showed CER-1236 specificity to TIM-L-4, which investigators concluded that combined with the lack of association with clinically relevant toxicity, may make the compound an attractive option for treating ovarian cancer.
georgie18
Member Level
Re: georgie18 post# 384735
Tuesday, October 29, 2024 10:18:14 AM
Post#
384978
of 385445
CERO...0817...HOD...Alerted at .0843...Looks like she wants to turn up here...🥳
georgie18
Member Level
Re: georgie18 post# 161
Wednesday, October 23, 2024 8:43:17 AM
Post#
162
of 162
CERO...884...off my .0843 Alert...🥳
georgie18
Member Level
Re: georgie18 post# 384664
Tuesday, October 22, 2024 4:54:59 PM
Post#
384719
of 384734
CERO...Churned a lot of .08s today...🥳
georgie18
Member Level
Re: None
Tuesday, October 22, 2024 9:21:41 AM
Post#
160
of 160
CERO...0843...🥳...Bullish Piercing Line on the close last night...Scaling in with some volume hitting this morning...
News 
Market Data 
Discover 
AI
